Drug Names
AstraZeneca Advancing Plan to Launch Biomarker-Driven Drugs as Alternative to Chemo in Breast Cancer
Premium
The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.
FDA Approves Genentech's Itovebi Combo for PIK3CA-Mutated Advanced Breast Cancer Patients
In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.
AstraZeneca, Daiichi Sankyo's Enhertu BLA in HER2-Low, Ultralow Breast Cancer Gets FDA Priority Review
The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.
FDA Grants Full Approval to Eli Lilly's Retevmo in RET-Mutant Medullary Thyroid Cancer
The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.
Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to FGFR-directed therapy.
Sep 9, 2024